Преэклампсия: современные концепции патогенеза

1. Ives C.W., Sinkey R., Rajapreyar I., Tita A.T.N., Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020; 76(14): 1690-702. https://dx.doi.org/10.1016/j.jacc.2020.08.014.
2. Nirupama R., Divyashree S., Janhavi P., Muthukumar S.P., Ravindra P.V. Preeclampsia: pathophysiology and management. J. Gynecol. Obstet. Hum. Reprod. 2021; 50(2):101975. https://dx.doi.org/10.1016/j.jogoh.2020.101975.
3. Poon L.C., Shennan A., Hyett J.A., Kapur A., Hadar E., Divakar H. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet. 2019; 145(Suppl. 1): 1-33. https://dx.doi.org/10.1002/ijgo.12802.
4. Wójtowicz A., Zembala-Szczerba M., Babczyk D., Kołodziejczyk-Pietruszka M., Lewaczyńska O., Huras H. Early- and late-onset preeclampsia: a comprehensive cohort study of laboratory and clinical findings according to the new ISHHP criteria. Int. J. Hypertens. 2019; 2019: 4108271.https://dx.doi.org/10.1155/2019/4108271.
5. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy. Obstet. Gynecol. 2019; 133(1): e26-e50.
6. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet. Gynecol. 2020; 135(6): e237-e260. https://dx.doi.org/10.1097/AOG.0000000000003020.
7. Гайсин И.Р., Исхакова А.С. Диагностика и лечение гипертензивных состояний беременности. Артериальная гипертензия. 2021; 27(2): 146-69.https://dx.doi.org/10.18705/1607-419X2021-27-2-146-169.
8. Helmo F.R., Lopes A.M.M., Carneiro A.C.D.M., Campos C.G., Silva P.B., Dos Reis Monteiro M.L.G. et al. Angiogenic and antiangiogenic factors in preeclampsia. Pathol. Res. Pract. 2018; 214(1): 7-14. https://dx.doi.org/10.1016/j.prp.2017.10.021.
9. Garrido-Gómez T., Castillo-Marco N., Cordero T., Simón C. Decidualization resistance in the origin of preeclampsia. Am. J. Obstet. Gynecol. 2022; 226(2, Suppl.): S886-94. https://dx.doi.org/10.1016/j.ajog.2020.09.039.
10. Hariharan N., Shoemaker A., Wagner S. Pathophysiology of hypertension in preeclampsia. Microvasc. Res. 2017; 109: 34-7. https://dx.doi.org/10.1016/j.mvr.2016.10.002.
11. El-Sayed A.A.F. Preeclampsia: a review of the pathogenesis and possible management strategies based on its pathophysiological derangements. Taiwan. J. Obstet. Gynecol. 2017; 56(5): 593-8. https://dx.doi.org/10.1016/j.tjog.2017.08.004.
12. Staff A.C., Fjeldstad H.E., Fosheim I.K., Moe K., Turowski G., Johnsen G.M. et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am. J. Obstet. Gynecol. 2022; 226(2, Suppl.): S895-906.https://dx.doi.org/10.1016/j.ajog.2020.09.026.
13. James-Allan L.B., Whitley G.S., Leslie K., Wallace A.E., Cartwright J.E. Decidual cell regulation of trophoblast is altered in pregnancies at risk of pre-eclampsia. J. Mol. Endocrinol. 2018; 60(3): 239-46. https://dx.doi.org/10.1530/JME-17-0243.
14. Falco M.L., Sivanathan J., Laoreti A., Thilaganathan B., Khalil A. Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2017; 50(3): 295-301.https://dx.doi.org/10.1002/uog.17494.
15. Wadhwani P., Saha P.K., Kalra J.K., Gainder S., Sundaram V. A study to compare maternal and perinatal outcome in early vs. late onset preeclampsia. Obstet. Gynecol. Sci. 2020; 63(3): 270-7. https://dx.doi.org/10.5468/ogs.2020.63.3.270.
16. Burton G.J., Redman C.W., Roberts J.M., Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019; 366: l2381.https://dx.doi.org/10.1136/bmj.l2381.
17. Labarrere C.A., DiCarlo H.L., Bammerlin E., Hardin J.W., Kim Y.M., Chaemsaithong P. et al. Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. Am. J. Obstet. Gynecol. 2017; 216(3): 287.e1-287.e16.https://dx.doi.org/10.1016/j.ajog.2016.12.029.
18. Tomimatsu T., Mimura K., Matsuzaki S., Endo M., Kumasawa K., Kimura T. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. Int. J. Mol. Sci. 2019; 20(17): 4246. https://dx.doi.org/10.3390/ijms20174246.
19. Cerdeira A.S., Agrawal S., Staff A.C., Redman C.W., Vatish M. Angiogenic factors: potential to change clinical practice in pre-eclampsia? BJOG. 2018; 125(11): 1389-95. https://dx.doi.org/10.1111/1471-0528.15042.
20. Борис Д.А., Волгина Н.Е., Красный А.М., Тютюнник В.Л., Кан Н.Е. Прогнозирование преэклампсии по содержанию CD16-негативных моноцитов. Акушерство и гинекология. 2019; 7: 49-55.https://dx.doi.org/10.18565/aig.2019.7.49-55.
21. Melchiorre K., Giorgione V., Thilaganathan B. The placenta and preeclampsia: villain or victim? Am. J. Obstet. Gynecol. 2022; 226(2, Suppl.): S954-62.https://dx.doi.org/10.1016/j.ajog.2020.10.024.
22. McMaster-Fay R.A. Uteroplacental vascular syndromes: theories, hypotheses and controversies. Clin. Obstet. Gynecol. Reprod. Med. 2018; 4(6): 2-5.https://dx.doi.org/10.15761/COGRM.1000239.
23. Ходжаева З.С., Холин А.М., Шувалова М.П., Иванец Т.Ю., Демура С.А., Галичкина И.В. Российская модель оценки эффективности теста на преэклампсию sFlt-1/PlGF. Акушерство и гинекология. 2019; 2: 52-8. https://dx.doi.org/10.18565/aig.2019.2.52-58.
24. Pérez-Roque L., Núñez-Gómez E., Rodríguez-Barbero A., Bernabéu C., López-Novoa J.M., Pericacho M. Pregnancy-induced high plasma levels of soluble endoglin in mice lead to preeclampsia symptoms and placental abnormalities. Int. J. Mol. Sci. 2020; 22(1): 165. https://dx.doi.org/10.3390/ijms22010165.
25. Travaglino A., Raffone A., Saccone G., Migliorini S., Maruotti G.M., Esposito G. et al. Placental morphology, apoptosis, angiogenesis and epithelial mechanisms in early-onset preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 234: 200-6. https://dx.doi.org/10.1016/j.ejogrb.2018.12.039.
26. Phipps E., Prasanna D., Brima W., Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin. J. Am. Soc. Nephrol. 2016; 11(6): 1102-13. https://dx.doi.org/10.2215/CJN.12081115.
27. Nogueira Reis Z.S., Pereira J.B., Costa L.A.C., Barra J.S. Soluble endoglin in urine as an early-pregnancy preeclampsia marker: antenatal longitudinal feasibility study. J. Obstet. Gynaecol. 2021; 41(5): 693-8. https://dx.doi.org/10.1080/01443615.2020.1789851.
28. Perucci L.O., Gomes K.B., Freitas L.G., Godoi L.C., Alpoim P.N., Pinheiro M.B. et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS One. 2014; 9(5): e97632. https://dx.doi.org/10.1371/journal.pone.0097632.
29. Zhang L., Li X., Zhou C., You Z., Zhang J., Cao G. The diagnosis values of serum STAT4 and sEng in preeclampsia. J. Clin. Lab. Anal. 2020; 34(2): e23073. https://dx.doi.org/10.1002/jcla.23073.
30. Iriyama T., Wang W., Parchim N.F., Song A., Blackwell S.C., Sibai B.M. et al. Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015; 65(6): 1307-15. https://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05314.
31. Sriyanti R., Mose J.C., Masrul M., Suharti N. The difference in maternal serum hypoxia-inducible factors-1α levels between early onset and late-onset preeclampsia. Open Access Maced. J. Med. Sci. 2019; 7(13): 2133-7.https://dx.doi.org/10.3889/oamjms.2019.601.
32. Albers R.E., Kaufman M.R., Natale B.V., Keoni C., Kulkarni-Datar K., Min S. et al. Trophoblast-specific expression of Hif-1α results in preeclampsia-like symptoms and fetal growth restriction. Sci. Rep. 2019; 9(1): 2742.https://dx.doi.org/10.1038/s41598-019-39426-5.
33. Harati-Sadegh M., Kohan L., Teimoori B., Mehrabani M., Salimi S. The association of the placental Hypoxia-inducible factor1-α polymorphisms and HIF1-α mRNA expression with preeclampsia. Placenta. 2018; 67: 31-7.https://dx.doi.org/10.1016/j.placenta.2018.05.005.
34. Kimura C., Watanabe K., Iwasaki A., Mori T., Matsushita H., Shinohara K., Wakatsuki A. The severity of hypoxic changes and oxidative DNA damage in the placenta of early-onset preeclamptic women and fetal growth restriction. J. Matern. Fetal Neonatal Med. 2013; 26(5): 491-6. https://dx.doi.org/10.3109/14767058.2012.733766.
35. Ma Y., Ye Y., Zhang J., Ruan C.C., Gao P.J. Immune imbalance is associated with the development of preeclampsia. Medicine (Baltimore). 2019; 98(14): e15080. https://dx.doi.org/10.1097/MD.0000000000015080.
36. Elchaninov A.V., Fatkhudinov T.K., Vishnyakova P.A., Lokhonina A.V., Sukhikh G.T. Phenotypical and functional polymorphism of liver resident macrophages. Cells. 2019; 8(9): 1032. https://dx.doi.org/10.3390/cells8091032.
37. Борис Д.А., Тютюнник В.Л., Кан Н.Е., Щеголев А.И., Синицына В.А., Садекова А.А., Красный А.М. Особенности изменения клеток моноцитарно-макрофагального звена в плаценте при преэклампсии. Акушерство и гинекология. 2021; 10: 48-54. https://dx.doi.org/10.18565/aig.2021.10.48-54.
38. Jung E., Romero R., Yeo L., Gomez-Lopez N., Chaemsaithong P., Jaovisidha A. et al. The etiology of preeclampsia. Am. J. Obstet. Gynecol. 2022; 226(2, Suppl.): S844-66. https://dx.doi.org/10.1016/j.ajog.2021.11.1356.
39. Mruma H.A., McQuillan R., Norrie J. The association of malaria infection and gestational hypertension in Africa: systematic review and meta-analysis. J. Glob. Health. 2020; 10(2): 020417. https://dx.doi.org/10.7189/jogh.10.020417.
40. Shiadeh M.N., Riahi S.M., Khani S., Alizadeh S., Hosseinzadeh R., Hasanpour A.H. et al. Human immunodeficiency virus and risk of pre-eclampsia and eclampsia in pregnant women: a meta-analysis on cohort studies. Pregnancy Hypertens. 2019; 17: 269-75. https://dx.doi.org/10.1016/j.preghy.2019.07.008.
41. Pereira M.M., Mainigi M., Strauss J.F. Secretory products of the corpus luteum and preeclampsia. Hum. Reprod. Update. 2021; 27(4): 651-72.https://dx.doi.org/10.1093/humupd/dmab003.
42. Lan K.C., Lai Y.J., Cheng H.H., Tsai N.C., Su Y.T., Tsai C.C., Hsu T.Y. Levels of sex steroid hormones and their receptors in women with preeclampsia. Reprod. Biol. Endocrinol. 2020; 18(1): 12. https://dx.doi.org/10.1186/s12958-020-0569-5.
43. Shin Y.Y., Jeong J.S., Park M.N., Lee J.E., An S.M., Cho W.S. et al. Regulation of steroid hormones in the placenta and serum of women with preeclampsia. Mol. Med. Rep. 2018; 17(2): 2681-8. https://dx.doi.org/10.3892/mmr.2017.8165.
44. Wan J., Hu Z., Zeng K., Yin Y., Zhao M., Chen M., Chen Q. The reduction in circulating levels of estrogen and progesterone in women with preeclampsia. Pregnancy Hypertens. 2018; 11: 18-25. https://dx.doi.org/10.1016/j.preghy.2017.12.003.
45. Nezi M., Mastorakos G., Mouslech Z., Feingold K.R., Anawalt B., Boyce A. et al.; eds. Corticotropin releasing hormone and the immune/inflammatory response. In: Endotext
46. Peixoto A.B., Rolo L.C., Nardozza L.M.M., Araujo Júnior E. Epigenetics and preeclampsia: programming of future outcomes. Methods Mol. Biol. 2018; 1710: 73-83. https://dx.doi.org/10.1007/978-1-4939-7498-6_6.
47. Apicella C., Ruano C.S.M., Méhats C., Miralles F., Vaiman D. The role of epigenetics in placental development and the etiology of preeclampsia. Int. J. Mol. Sci. 2019; 20(11): 2837. https://dx.doi.org/10.3390/ijms20112837.
48. Phipps E.A., Thadhani R., Benzing T., Karumanchi S.A. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat. Rev. Nephrol. 2019; 15(5): 275-89. https://dx.doi.org/10.1038/s41581-019-0119-6. Erratum in: Nat. Rev. Nephrol. 2019; 15(6): 386.
49. Feng Y., Lian X., Guo K., Zhang G., Huang X. A comprehensive analysis of metabolomics and transcriptomics to reveal major metabolic pathways and potential biomarkers of human preeclampsia placenta. Front. Genet. 2022; 13: 1010657. https://dx.doi.org/10.3389/fgene.2022.1010657.
50. Méhats C., Miralles F., Vaiman D. Nouveaux regards sur la prééclampsie

Поступила 07.08.2022

Принята в печать 22.11.2022